Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up

Journal of Hepatology

Volumn 48, Issue 6, 2008, Pages 923-931

  Yatsuji, Hiromi ^a   Suzuki, Fumitaka ^a   Sezaki, Hitomi ^a   Akuta, Norio ^a   Suzuki, Yoshiyuki ^a   Kawamura, Yusuke ^a   Hosaka, Tetsuya ^a   Kobayashi, Masahiro ^a   Saitoh, Satoshi ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Watahiki, Sachiyo ^a   Iwasaki, Satomi ^a   Kobayashi, Mariko ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Adefovir dipivoxil; Combination therapy; Hepatitis B virus; Lamivudine resistant mutant; rtA181T; rtN236T

Indexed keywords

ADEFOVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; VIRUS REPLICATION;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PHOSPHONIC ACIDS; RISK FACTORS; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 43049168909     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.02.019     Document Type: Article

References (28)

1. Ganem D., and Prince A.M. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350 (2004) 1118-1129
2. Wright T.L., and Lau J.Y. Clinical aspects of hepatitis B virus infection. Lancet 342 (1993) 1340-1344
3. Lai C.L., Leung N., Teo E.K., Tong M., Wong F., Hann H.W., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536
4. Chan H.L.Y., Heathcote E.J., Marcellin P., Lai C.L., Cho M., Moon Y.M., et al. Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Int Med 147 (2007) 745-754
5. Nevens F., Main J., Honkoop P., Tyrrell D.L., Barber J., Sullivan M.T., et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 113 (1997) 1258-1263
6. Lai C.L., Chien R.N., Leung N.W., Chang T.T., Guan R., Tai D.I., et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339 (1998) 61-68
7. Suzuki Y., Kumada H., Ikeda K., Chayama K., Arase Y., Saitoh S., et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 30 (1999) 743-748
8. Lai C.L., Dienstag J., Schiff E., Leung N.W., Atkins M., Hunt C., et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36 (2003) 687-696
9. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
10. Colonno R.J., Rose R., Baldick C.J., Levine S., Pokornowski K., Yu C.F., et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44 (2006) 1656-1665
11. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27 (1998) 1670-1677
12. Delaney W.E., Yang H., Westland C.E., Das K., Arnold E., Gibbs C.S., et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77 (2003) 11833-11841
13. Sherman M., Yurdaydin C., Sollano J., Silva M., Liaw Y.F., Cianciara J., et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130 (2006) 2039-2049
14. Rapti I., Dimou E., Mitsoula P., and Hadziyannis S.J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45 (2007) 307-313
15. Lee Y.S., Suh D.J., Lim Y.S., Jung S.W., Kim K.M., Lee H.C., et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43 (2006) 1385-1391
16. Perrillo R., Hann H.W., Mutimer D., Willems B., Leung N., Lee W.M., et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126 (2004) 81-90
17. Hosaka T., Suzuki F., Suzuki Y., Saitoh S., Kobayashi M., Someya T., et al. Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus. Intervirology 47 (2004) 362-369
18. Usuda S., Okamoto H., Iwanari H., Baba K., Tsuda F., Miyakawa Y., et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 80 (1999) 97-112
19. Peters M.G., Hann Hw H., Martin P., Heathcote E.J., Buggisch P., Rubin R., et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126 (2004) 91-101
20. Buti M., Elefsiniotis I., Jardi R., Vargas V., Rodriguez-Frias F., Schapper M., et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol 47 (2007) 366-372
21. Lampertico P., Viganò M., Manenti E., Iavarone M., Sablon E., and Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133 (2007) 1445-1451
22. Lampertico P., Viganò M., Manenti E., Iavarone M., Lunghi G., and Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 42 (2005) 1414-1419
23. Yeh C.T., Chien R.N., Chu C.M., and Liaw Y.F. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 31 (2000) 1318-1326
24. Brunelle M.N., Jacquard A.C., Pichoud C., Durantel D., Carrouee-Durantel S., Villeneuve J.P., et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41 (2005) 1391-1398
25. Yatsuji H., Noguchi C., Hiraga N., Mori N., Tsuge M., Imamura M., et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother 50 (2006) 3867-3874
26. Borroto-Esoda K., Miller M.D., and Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir deipivoxil clinical trials. J Hepatol 47 (2007) 492-498
27. Van Bommel F., Wunsche T., Mauss S., Reinke P., Bergk A., Schurmann D., et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40 (2004) 1421-1425
28. van Bommel F., Zollner B., Sarrazin C., Spengler U., Huppe D., Moller B., et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 44 (2006) 318-325